CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
종목 코드 CVRX
회사 이름CVRx Inc
상장일Jun 30, 2021
CEOMr. Kevin Hykes
직원 수206
유형Ordinary Share
회계 연도 종료Jun 30
주소9201 West Broadway Avenue
도시MINNEAPOLIS
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호55445
전화17634162850
웹사이트https://www.cvrx.com/
종목 코드 CVRX
상장일Jun 30, 2021
CEOMr. Kevin Hykes
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음